GSK's depemokimab under review in China and Japan for asthma, CRSwNP
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...
GSK applications for sinus disease treatment accepted for review
(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...
GlobalData on MSN23d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab ... s Nucala for CRSwNP treatment" was originally created and published by Pharmaceutical Technology, a ...
FierceBiotech2d
GSK offers up to £50M to conduct cancer vaccine research with the University of Oxford
British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...